Virology Group

Grants

2022-2026

The role of glycosylation of structural proteins in the life cycle of SARS-CoV-2 coronavirus

dr hab. Ewelina Król, prof. UG

NCN – OPUS 21

2022-2026

Universal vaccine against SARS-CoV-2 variants based on conserved spike protein epitopes – vaccine efficacy studies in vitro and in vivo

dr Katarzyna Grzyb

NCN – OPUS 21

2022-2024

The role of O-glycosylation of Zika virus envelope proteins in the replication cycle and its influence on antigenicity

mgr Gabriela Brzuska

NCN – PRELUDIUM 20

2021-2027

Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases

prof. Bogusław Szewczyk

 

The aim of the project is to develop vaccine candidates based on mRNA/VLP technology against one of three zoonotic viral pathogens (SARS-CoV-2 coronavirus, Tick-Borne Encephalitis Virus, TBEV and West Nile virus, WNV) that are of great importance to human health around the world.

The development path started from designing the mRNA encoding for virus antigens, through the potential vaccine candidate evaluation, preclinical and I phase of the clinical studies. The whole project is divided into 10 tasks. They include a research stage using mRNA/VLP technology and a development stage of the production and analysis process on a laboratory and pilot scale.

The suspected project effect combines the advantages of both mRNA and VLPs: high effectiveness, long-lasting, the beginning of the dosing regimen, the possibility of storage in convenient conditions and safety in addition to control and pediatric use.

Project co-financed by the state from the Medical Research Agency, in the competition: Development of new technologies using RNA technology

The consortium consists of:

– Adamed Sp. Zoo. (Project leader)

– University of Gdansk

– Institute of Biotechnology and Biophysics of the Polish Academy of Sciences

Project value PLN 87,517,519.25, including PLN 11,382,750.00 for UG

Funding PLN 58,494,498.19

Medical Research Agency (ABM)

2021-2025

Immunomodulatory properties of SARS-CoV-2 coronavirus-encoded proteins

dr Andrea Lipińska

NCN – OPUS 20

2021-2025

Cell-to-cell transmission of SARS-CoV-2

prof. dr hab. Krystyna Bieńkowska-Szewczyk

NCN – PRELUDIUM BIS 2

2020-2024

Mammalian cell delivery of stable therapeutic mRNA packaged inside virus-like particles

prof. dr hab. Bogusław Szewczyk

NCN – OPUS 17

2020-2022

Towards safe anti-SARS-CoV-2 coronavirus vaccine – modifications of the spike protein leading to the elimination of ADE effect.

dr hab. Ewelina Król, prof. UG

NCN – Szybka ścieżka dostępu do funduszy na badania nad COVID-19

2020-2022

Hijacking the ubiquitin-proteasome system by the UL49.5 protein of bovine herpesvirus 1 as an immune evasion strategy – elucidating the mechanismof TAP transporter degradation

mgr Magda Wąchalska

NCN – PRELUDIUM 18

2020-2022

Participation of cellular proteins in the inhibition of antigen presentation dependent on UL49.5 protein of bovine herpesvirus BHV-1

mgr Magda Wąchalska

NCN – ETIUDA 8

2018-2022

Antiviral activity of interferon induced transmembrane proteins (IFITM) as a novel therapeutic strategy to control viral infections – evaluation in vitro and in vivo

dr Alicja Chmielewska

FNP – POWROTY

2018 - 2021

Immunogenic properties of hepatitis C virus NS3 protein epitopes fused to hepatitis B small surface antigen

dr Katarzyna Grzyb

NCN – OPUS 14

2017-2021

Public health risk assessment, associated with potentially dangerous zoonotic influenza A virus strains, circulating among livestock in Poland

dr Krzysztof Łepek

NCN – SONATA 11

2017 - 2020

Anti-Zika vaccine – innovative methods for antigen construction

dr Ewelina Król

NCBiR – LIDER VII

2017 - 2020

Virus-like particles produced in life bioreactors as Vaccine against the most dangerous disease of poultry

dr Łukasz Rąbalski

NCBiR – LIDER VII

2017 - 2020

Evaluation of the immunogenicity of the highly conserved Hepatitis C virus E2 glycoprotein epitopes exposed on the surface of the Hepatitis B small surface antigen virus-like particles

mgr Anna Czarnota

NCN – PRELUDIUM 12

2016-2020

Tick-borne encephalitis virus – search for mechanisms useful in treatment and prophylaxis

dr Ewelina Król

NCN – SONATA 10

2016-2020

Genetic factors causing increased virulence of the baculovirus infectingone of the major forest pests – the gypsy moth (Lymantria dispar)

mgr Martyna Krejmer

NCN – PRELUDIUM 9

2016-2019

Novel biocontrol agent for use in organic / IPM citrus cultivation: biology, phylogeny and biopesticide activity

prof. dr hab. Bogusław Szewczyk

NCBiR – Konkurs na wspólne polsko – południowo afrykańskie projekty badawcze

2016-2019

NanoExpo system as a innovative technological process of production of next generation vaccines

mgr Beata Gromadzka

NCBiR – LIDR VI

2015-2021

The molecular mechanism of activity of alphaherpesvirus-encoded key immune evasion proteins

dr Andrea Lipińska

NCN – SONATA BIS 4

2015-2017

Influenza vaccine – innovative methods for antigen preparation

prof. dr hab. Bogusław Szewczyk

NCBiR – PBS

2015-2016

Modern Newcastle disease vaccine

dr Łukasz Rąbalski

FNP – IMPULS

2015

An ecological alternative to excessive chemicalisation of environment. Search and characterization of natural enemies of forest pests

dr Łukasz Rąbalski

FNP – SKILLS

2013-2017

Oral vaccine against influenza virus for poultry

dr Dawid Nidzworski

NCBiR – LIDER IV

2013-2017

Biochemical, functional and immunological properties of new recombinant envelope glycoproteins and virus-like particles of hepatitis C virus

dr Katarzyna Grzyb

NCN – SONATA 3

2013-2014

Improvement of anvitiral neutralizing antibodies

mgr Krzysztof Lacek

FNP – JUVENTUS PLUS

2012-2018

Mechanisms of virus cell-to-cell spread: virus survival strategies

prof. dr hab. Krystyna Bieńkowska – Szewczyk

NCN – MAESTRO 2

2012-2015

Construction and technological assessment of a vector vaccine against Newcastle disease (ND) in chickens

prof. dr hab. Bogusław Szewczyk

NCBiR – PBS 1

2012-2015

New recombinant glycoproteins E1E2 and virus-like particles for vaccines against hepatitis C virus (HCV)

dr Katarzyna Grzyb

NCBiR – LIDER III

2012-2015

Correlation between DNA sequence of selected genes of gypsy moth baculovirus (LdMNPV) and their virulence

mgr Łukasz Rąbalski

NCN – PRELUDIUM 2

2012-2015

Role of egzosomes in alphaherpesvirus infection

dr Andrea Lipińska

NCN – SONATA 2

2012-2015

The influence of tunicamycin analogues and mimetics on hepatitis C virus (HCV) Propagation

dr Ewelina Król

NCN – PRELUDIUM 2

2011-2014

Exploring new immune evasion mechanisms of herpesviruses: the search for improvement strategies of anti-herpesviral vaccines and virus-based therapeutics

dr Andrea Lipińska

FNP – POMOST

2010-2013

Development of biosensor for detection of influenza virus in environmental samples

mgr Dawid Nidzworski

FNP – VENTURES

2010-2011

Strategies of alphaherpesviruses spread from cell to cell

mgr Agnieszka Brzozowska

FNP – IUVENTUS PLUS

2010-2011

Glycosylation inhibitors as new antiviral agents against different strains of Influenza virus type A

mgr Ewelina Król

FNP – IUVENTUS PLUS

2008-2015

CENTRE OF MEDICINAL PRODUCT BIOTECHNOLOGY. Package of innovative biopharmaceuticals for human and animal therapy and prophylactics

prof. dr hab. Bogusław Szewczyk

MNiSW – POIG

2007-2012

New preventative and therapeutic Hepatitis C vaccines: from pre-clinical to phase 1, HEPACIVAC

prof. dr hab. Krystyna Bieńkowska – Szewczyk,
Coordinator : R. Cortese, Italy

 

6th EU Framework Program grant, Quality of Life, Priority

2007-2012

New vaccines against Hepatitis C virus (HCV)

prof. dr hab. Krystyna Bieńkowska – Szewczyk

MNiSW SPUB
(co-financing of EU project)

2006-2010

Entry inhibitors for the treatment of hepatitis C virus infection (EI-HCV)

prof. dr hab. Krystyna Bieńkowska – Szewczyk,
Coordinator: J. Ball. UK

6th EU Framework Program grant, Quality of Life,
Marie Curie Research Training Network

2006-2009

Multifunctional herpesvirus proteins : key elements for vaccine development

prof. dr hab. Krystyna Bieńkowska – Szewczyk

MNiSW

2005-2007

Contribution of immediate- early proteins of pseudorabies virus (PRV; Suid herpes1) to the antiviral protective immune response

Collaborating institution: Federal Research Centre for Virus Disease of Animals,
Institute of Immunology,  Dr Hanns – Joachim Rziha

Polish – German bilateral collaboration grant
(Ministry of Agriculture)

2004-2007

Classical swine fever virus (CSFV) as a model for testing new methods of inhibition of hepatitis C virus (HCV)

prof. dr hab. Bogusław Szewczyk

Grant KBN

2003-2005

Role of egzosomes in alphaherpesvirus infection

dr Andrea Lipińska

NCN – SONATA 2

2003-2005

Expression library immunisation (ELI) designed vaccines against infectious diseases in pigs; rapid identification of immunoprotective antigens and optimal antigen delivery systems

prof. dr hab. Krystyna Bieńkowska – Szewczyk

5th EU Framework Program grant

2002-2005

Role of cytoplasmic tails of viral envelope glycoproteins in immune evasion processes of pseudorabies virus”

prof. dr hab. Krystyna Bieńkowska – Szewczyk

Collaboration with Ghent University, dr Hans Nauwynck

Polish – Flemish, bilateral coorperation program
Project founded by Flanders government,
research conducted in Poland and Belgium

2002-2005

Structural and functional studies of hepatitis C virus glycoproteins: identification of targets for antiviral therapy

prof. dr hab. Krystyna Bieńkowska – Szewczyk

European Network for Hepatitis C Virus Envelope Glycoprotein Research (ENHCV)

5th EU Framework Program grant

2002-2004

Multicomponent and vector vaccines against helminth parasite infections in calves and sheep

prof. dr hab. Krystyna Bieńkowska – Szewczyk

Grant KBN